<DOC>
	<DOCNO>NCT03011775</DOCNO>
	<brief_summary>Pioglitazone , medication thiazolidinedione group , capable trigger peroxisome proliferator-activated receptor ( PPAR-γ ) . Activation receptor PPAR-γ regulate carbohydrate lipid metabolism , immune inflammatory response heart tissue . Our aim study effect pioglitazone insulin resistance , clinical course atherosclerosis coronary heart disease ( CHD ) . The study include 43 patient coronary artery disease . Patients divide study group - 20 patient , pioglitazone include combined therapy dose 15 mg 1 time per day morning , control group - 23 patient receive standard complex drug therapy 6 month . Patients underwent clinical examination , ultrasound neck vessel , study carbohydrate lipid metabolism . The end primary point study onset death due myocardial infarction , coronary revascularization procedure ( coronary artery bypass grafting ( CABG ) percutaneous coronary intervention ( PCI ) ) , hospitalization acute coronary syndrome ( ACS ) unstable angina ( UA ) . Predefined secondary end point include carotic atherosclerotic leisure ( carotic intima-media thickness , diameter stenosis , present atherosclerotic plaque ) , systemic inflammation level ( level C reactive protein ) , lipid metabolism ( level serum total cholesterol , triglyceride , high low density lipoprotein ) , level insulin resistance ( oral glucose tolerance test , blood glucose ) .</brief_summary>
	<brief_title>Effect Pioglitazone Insulin Resistance , Atherosclerosis Progression Clinical Course Coronary Heart Disease</brief_title>
	<detailed_description>The study include 43 people age 45 68 suffer ischemic heart disease . Before start study , participant give write informed consent , obtain Commission Bioethics Ukrainian Medical Stomatological Academy . Inclusion criterion follow : stable exertional angina , type 2 diabetes mellitus ( DM ) without receive injectable antidiabetic drug . Exclusion criterion : presence myocardial infarction history , intervention , malignant arterial hypertension ( AH ) , chronic heart failure ( HF ) III-IV functional class ( FC ) , systemic connective tissue disease , cancer oncohematological disease , severe infectious disease , chronic inflammatory disease , history acute cerebrovascular accident , disorder cardiac rhythm atrial fibrillation type . The end study primary point : onset death due myocardial infarction , coronary revascularization procedure ( coronary artery bypass grafting ( CABG ) percutaneous coronary intervention ( PCI ) ) , hospitalization acute coronary syndrome ( ACS ) unstable angina ( UA ) . The diagnosis CHD patient confirm presence FC I-III angina accord classification Canadian Cardiovascular Society phenomena circulatory insufficiency accord classification New York Heart Association ( NYHA ) . Bicycle ergometry perform `` Veloergotest 05 '' ( Ukraine ) via step increase load capacity consequent increase control electrocardiogram ( ECG ) BP . The force step I 150 kgm / min ( 25 W ) ; II - 300 kgm / min ( 50 W ) ; III - 450 kgm / min ( 75 W ) ; IV - 600 kgm / min ( 100 W ) ; V - 750 kgm / min ( 125 W ) ; VI - 900 kgm / min ( 150 W ) , duration step 3 minute . Tolerance CHD patient exercise calculate value threshold load capacity volume work perform . The threshold load capacity 150 kgm / min ( 25 W ) consider low consistent angina FC IV ; 300 kgm / min ( 50 W ) - low , FC III ; 450-600 kgm / min ( 75-100 W ) - average , FC II ; 750 kgm / min ( 125 W ) - high exercise capacity , FC I . The criteria cease bicycle ergometry termination conventional clinical ECG sign myocardial ischemia . Prior inclusion clinical trial , patient receive conventional treatment screen examination verify diagnosis coronary heart disease type 2 diabetes . After screen , select 43 patient received standard medical therapy complex : isosorbide dinitrate 10-20 mg 2 time day , acetylsalicylic acid 75 mg 1 time day , bisoprolol 2.5 mg 1 time day , rosuvastatin 20 mg 1 time day , ramipril 5 mg 1 time day . Patients also receive recommendation diet lifestyle change . Patients receive conventional treatment least one month achieve stable parameter . On first day study , blood sample take patient , clinical examination conduct . After clinical laboratory study , patient randomize gender , age severity clinical manifestation coronary heart disease . As result randomization , patient divide study group ( n = 20 ) control group ( n = 23 ) . The complex therapy study group include pioglitazone 15 mg 1 time per day morning ( `` Pioglar '' , Ranbaxy , India ) 6 month . Patients control group continue receive standard set drug therapy . Re-examination carry 6 month . The examination include collection medical history objective data ( gender , age , overweight obesity , hypertension , type 2 diabetes ) . Patients evaluate anthropometric indicator ( height , weight , body mass index ( BMI ) ) , blood pressure - systolic diastolic ( SBP DBP ) , heart rate ( HR ) measure , ECG register . In order determine status vascular bed , patient underwent ultrasonography ( US ) neck vessel `` ULTIMA PA '' , sensor L5 - 12/40 , accordance standard protocol B-mode three level vascular bed bilaterally end diastole : proximal , medial distal point distance 1 cm bifurcation posterior wall right leave common carotid artery ( RCCA LCCA , respectively ) distant transducer unit . Contour carotid artery register , inner lumen , indicator ASP presence ( size , localization ) record , well IMT carotid artery . IMT measure distance first second echogenic line locate site accord procedure Pignoli P. et al . The diameter RCCA , LCCA , internal carotid artery ( ICA ) assess end systole diastole distance IMT . Normal IMT consider less 0.9 mm ; CCA IMT &gt; 1.4 mm evaluate ASP , range 1.0-1.3 mm thicken IMT ( ESH , ESC , 2007 ) . The standard criterion diagnosis hemodynamically significant stenosis narrow arterial lumen 50 % . The volume laboratory test includ general clinical biochemical blood analysis . For control carbohydrate metabolism glycemic profile study determine fast glucose 1 hour take 75 g glucose ( oral glucose tolerance test , OGTT ) via glucose oxidase method ; hyperglycemic factor calculate . In patient lipid profile study : total cholesterol ( TC ) , triglyceride ( TG ) cholesterol high-density lipoprotein ( HDL ) ( `` Diakon-DS '' , Russia ) , content cholesterol low-density lipoprotein ( LDL ) low density lipoprotein ( VLDL ) calculate , well atherogenic factor ( AF ) . Study inflammatory response conduct determine concentration basic biomarkers - high-sensitivity C-reactive protein ( hs-CRP , `` DRG '' , USA ) , human tissue inhibitor metalloproteinase-1 ( TIMP-1 , `` eBioscience '' , Austria ) accord manufacturer 's protocols test system via immunoenzyme method . The presence microalbuminuria determine use test strip `` Mikroalbufan '' ( `` Lachema '' , Czech Republic ) , ratio albumin / creatinine urine calculate . Statistical processing perform use software `` Statistica 6.0 '' ( StatSoft , USA ) calculation average ( M ) standard error average ( ) . Methods descriptive statistic use , comparison performance group perform parametric ( Student 's t-test ) non-parametric ( Pearson χ2 test , Fisher 's exact test , Mann-Whitney test ) statistic . For type analysis difference p &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>stable exertional angina , type 2 diabetes mellitus ( DM ) without receive injectable antidiabetic drug presence myocardial infarction history , intervention ; malignant arterial hypertension ( AH ) ; chronic heart failure ( HF ) IIIIV functional class ( FC ) ; systemic connective tissue disease ; cancer oncohematological disease , severe infectious disease , chronic inflammatory disease ; history acute cerebrovascular accident ; disorder cardiac rhythm atrial fibrillation type .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pioglitazone , Insulin Resistance</keyword>
	<keyword>Atherosclerosis , Coronary Heart Disease</keyword>
</DOC>